Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3115_Библиотеки_им_академика_М_И_Перельмана
.pdf
Drazen J. M., Wood A. J. J. Trial Registration Report Card // The New England
journal of medicine. 2005. December 29. Vol. 353. P. 2809–2811.
Ioannidis J. P. A., Trikalinos T. A. Early extreme contradictory estimates may appear
in published research: The Proteus phenomenon in molecular genetics researchand
randomized trials // Journal of clinical epidemiology. 2005. Vol. 58. P. 543–549.
Ioannidis J. P. Effect of the statistical significance of results on the time to completion
and publication of randomized efficacy trials // JAMA. 1998. Vol. 279. № 4. P. 281–286.
Bekelman J. E., Li Y., Gross C. P. Scope and impact of financial conflicts of interest in
biomedical research: a systematic review // JAMA. 2003. January 22–29. Vol. 289. № 4. P.
454–465.
Bhandari M., Busse J. W., Jackowski D., Montori V. M., Schünemann H. et al.
Association between industry funding and statistically significant pro-industry findings in
medical and surgical randomized trials // CMAJ. 2004. February 17. Vol. 170. № 4. P. 477–
480.
Chalmers I. The true lorcainide story revealed // BMJ. 2015. Vol. 350, g7717
Cowley A. J., Skene A., Stainer K., Hampton J. R. The effect of lorcainide on
arrhythmias and survival in patients with acute myocardial infarction: an example of
publication bias // International journal of cardiology. 1993. July 1. Vol. 40. № 2. P. 161–
166.
De Angelis C., Drazen J. M., Frizelle F. A., Haug C., Hoey J., Horton R. et al. Clinical
trial registration: a statement from the International Committee of Medical Journal Editors
// The New England journal of medicine. 2004. September 16. Vol. 351. P. 1250–1251.
Barroso C. Epistemology of medical knowledge / Seising R., Tabacchi M. (eds).
Fuzziness and medicine: philosophical reflections and application systems in health care.
Studies in fuzziness and soft computing. Vol. 302. Springer, Berlin, Heidelberg, 2013.
Eddy D. M. Evidence-based medicine: a unified approach // Health Affairs. 2005. Vol.
24. № 1. P. 9–17.
Claridge J. A., Fabian T. C. History and development of evidence-based medicine //
World Journal of Surgery. 2005. Vol. 29. № 5. P. 547–553.
Van Baalen S. The epistemology of clinical decision-making: an epistemological
analysis of reasoning in clinical practice, and the role of technological measurements.
Master thesis. University of twente, 2014.
Goodman K. W. Ethics and evidence-based medicine. Fallibility and responsibility in
clinical science. Cambridge University Press, 2002.
Glasziou P., Chalmers I., Rawlings M., McCulloch P. When are randomised trials
unnecessary? Picking signal from noise // BMJ. 2007. Vol. 334. № 7589. P. 349–351.
Worrall J. Why There’s no cause to randomize // The British Journal for the Philosophy
of Science. 2007. Vol. 58. № 3. P. 451–488.
Counsell C. E., Clarke M. J., Slattery J. et al. The miracle of DICE therapy for acute
stroke: fact or fictional product of subgroup analysis? // BMJ. 1994. Vol. 309. P. 1677–
1681.
Konstam M. A., Weir M. R., Reicin A., Shapiro D., Sperling R. S., Barr E., Gertz B. J.
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib // Circulation.
2001. November 6. Vol. 104. № 19. P. 2280–2288.
https://t.me/medicina_free
De Leon J. Evidence-based medicine versus personalized medicine: are they enemies?
// Journal of Clinical Psychopharmacology. 2012. April. Vol. 32. № 2. P. 153–164.
Ioannidis J. P. The mass production of redundant, misleading, and conflicted
systematic reviews and meta-analyses // The Milbank quarterly. 2016. September. Vol. 94.
№ 3. P. 485–514.
Samet J. M. Epidemiology and the tobacco epidemic: how research on tobacco and
health shaped epidemiology // American Journal of Epidemiology. 2016. March 1. Vol. 183.
№ 5. P. 394–402.
Cochrane A. Sickness in Salonica: my first, worst, and most successful clinical trial //
British Medical Journal. 1984. December. Vol. 289. P. 1726–1727.
Simpson G. G. The therapiste and the researcher // Science. 1967. October 13. Vol.
158. № 3798. P. 246.
Cochrane A. L. Effectiveness and efficiency. London: Nuffield Provincial Hospitals
Trust, 1972.
Stavrou A., Challoumas D., Dimitrakakis G. Archibald Cochrane (1909–1988): the
father of evidence-based medicine // Interactive cardiovascular and thoracic surgery. 2014.
January. Vol. 18. № 1. P. 121–124.
Barron A. B., Maleszka R., Helliwell P. G., Robinson G. E. Effects of cocaine on
honey bee dance behaviour // The Journal of Experimental Biology. 2009. Vol. 212. P. 163–
168.
Chan K. A clinical trial gone awry: the Chocolate Happiness Undergoing More
Pleasantness (CHUMP) study // Canadian Medical Association journal. 2007. December 4.
Vol. 177. № 12. P. 1539–1541.
Schwartz M. A. The importance of stupidity in scientific research // Journal of cell
science. 2008. June 1. Vol. 121. № 11. P. 1771.
Shafik A. Effect of different types of textiles on sexual activity. Experimental study //
European urology. 1993. Vol. 24. № 3. P. 375–380.
Crowley P., Chalmers I., Keirse M. J. N. The effects of corticosteroid administration
before preterm delivery: an overview of the evidence from controlled trials // British Journal
of Obstetrics & Gynaecology. 1990. January. Vol. 97. № 1. P. 11–25.
Olson M. V. Precision medicine at the crossroads // Human genomics. 2017. Vol. 11.
P. 23.
Windsor B., Popovich I., Jordan V., Showell M., Shea B., Farquhar C. Methodological
quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane
systematic reviews in assisted reproductive technologies // Human reproduction. 2012.
December. Vol. 27. № 12. P. 3460–3466.
Fleming P. S., Seehra J., Polychronopoulou A., Fedorowicz Z., Pandis N. Cochrane
and non-Cochrane systematic reviews in leading orthodontic journals: a quality paradigm?
// The European Journal of Orthodontics. 2013. April. Vol. 35. № 2. P. 244–248.
Moseley A. M., Elkins M. R., Herbert R. D., Maher C. G., Sherrington C. Cochrane
reviews used more rigorous methods than non-Cochrane reviews: survey of systematic
reviews in physiotherapy // Journal of clinical epidemiology. 2009. October. Vol. 62. № 10.
P. 1021–1030.
Olsen O., Middleton P., Ezzo J. et al. Quality of Cochrane reviews: assessment of
sample from 1998 // BMJ. 2001. October. Vol. 323. № 7317. P. 829–832.
https://t.me/medicina_free
Clarke M., Chalmers I. Discussion sections in reports of controlled trials published in
general medical journals // JAMA. 1998. Vol. 280. № 3. P. 280–282.
Clarke M., Hopewell S., Chalmers I. Reports of clinical trials should begin and end
with up-to-date systematic reviews of other relevant evidence: a status report // Journal of
the Royal Society of Medicine. 2007. April. Vol. 100. P. 187–190.
Fergusson D., Glass K. C., Hutton B., Shapiro S. Randomized controlled trials of
aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? // Clinical
Trials. 2005. June 1. Vol. 2. № 3. P. 218–232.
LeLorier J., Grégoire G., Benhaddad A., Lapierre J., Derderian F. Discrepancies
between meta-analyses and subsequent large randomized, controlled trials // The New
England Journal of Medicine. 1997. August 21. Vol. 337. № 8. P. 536–542.
Amanullah S., Venkataraman R. The routine use of albumin for fluid resuscitation of
critically ill patients is not warranted // Critical Care. 2004. December. Vol. 8. № 6.
Sauerland S., Maegele M. A CRASH landing in severe head injury // Lancet. 2004.
October 9. Vol. 364. № 9442. P. 1291–1292.
Mirza R. D., Punja S., Vohra S., Guyatt G. The history and development of N of 1
trials // Journal of the Royal Society of Medicine. 2017. Vol. 110. № 8. P. 330–340.
Ioannidis J. P. A., Khoury M. J. Evidence-based medicine and big genomic data //
Human Molecular Genetics. 2018. May 1. Vol. 27. № R 1. P. R2–7.
Lillie E. O., Patay B., Diamant J., Issell B., Topol E. J., Schork N. J. The n-of-1
clinical trial: the ultimate strategy for individualizing medicine? // Personalized medicine.
2011. March. Vol. 8. № 2. P. 161–173.
Moore A., Derry S., Eccleston C., Kalso E. Expect analgesic failure; pursue analgesic
success // BMJ. 2013. Vol. 346. № 7911, f2690.
Wegman A., Van der Windt D. A., De Haan M., Deville W., Fo C., de Vries T. P.
Switching from NSAIDs to paracetamol: a series of n of 1 trials for individual patients with
osteoarthritis // Annals of the rheumatic diseases. 2003. December. Vol. 62. № 12. P. 1156–
1161.
Mahon J. L., Laupacis A., Hodder R. V., McKim D. A., Paterson N. A., Wood T. E. et
al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing
n of 1 trials to standard practice // Chest. 1999. January. Vol. 115. № 1. P. 38–48.
Pope J. E., Prashker M., Anderson J. The efficacy and cost effectiveness of N of 1
studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory
drugs in osteoarthritis // The Journal of Rheumatology. 2004. January. Vol. 31. № 1. P.
140–149.
Ledford H. Cancer-genome study challenges mouse “avatars” // Nature. 2017.
October 9.
Lai Y., Wei X., Lin S., Qin L., Cheng L., Li P. Current status and perspectives of
patient-derived xenograft models in cancer research // Journal of Hematology & Oncology.
2017. Vol. 10. P. 106.
Ferriss J. S., Rice L. W. The role of in vitro directed chemotherapy in epithelial
ovarian cancer // Reviews in obstetrics & gynecology. 2010. Spring. Vol. 3. № 2. P. 49–54.
Burstein H. J., Mangu P. B., Somerfield M. R., Schrag D., Samson D., Holt L. et al.
American Society of Clinical Oncology clinical practice guideline update on the use of
https://t.me/medicina_free
chemotherapy sensitivity and resistance assays // Journal of clinical oncology. 2011. August
20. Vol. 29. № 24. P. 3328–3330.
Gebelhoff R. Sequencing the genome creates so much data we don’t know what to do
with it // The Washington Post. 2015. July 7.
Goetz M. P., Kamal A., Ames M. M. Tamoxifen pharmacogenomics: the role of
CYP2D6 as a predictor of drug response // Clinical pharmacology and therapeutics. 2008.
January. Vol. 83. № 1. P. 160–166.
Rubin R. Precision medicine: the future or simply politics? // JAMA. 2015. Vol. 313.
№ 11. P. 1089–1091.
https://t.me/medicina_free
Часть шестая
Lindsay G. B., Merrill R. M., Hedin R. J. The contribution of public health and
improved social conditions to increased life expectancy: an analysis of public awareness //
Journal of Community Medicine and Health Education. 2014. Vol. 4. P. 311.
Ten great public health Achievements – United States, 1900–1999 // MMWR. 1999.
April 2. Vol. 48. № 12. P. 241–243.
Bunker J. P., Frazier H. S., Mosteller F. Improving health: measuring effects of medical
care // The Milbank quarterly. 1994. Vol. 72. № 2. P. 225–258.
McKinley J. B., McKinley S. M. The questionable contribution of medical measures to
the decline of mortality in the United States in the twentieth century // The Milbank
Memorial Fund quarterly. Health and society. 1977. Summer. Vol. 55. № 3. P. 405–428.
Bunker J. P. The role of medical care in contributing to health improvements within
societies // International Journal of Epidemiology. 2001. December 1. Vol. 30. № 6. P.
1260–1263.
Murray C. J. L. Why is Japanese life expectancy so high? // Lancet. 2011. September
24. Vol. 378. № 9797. P. 1124–1125.
Shiro Horiuchi Major causes of the rapid longevity extension in postwar Japan // The
Japanese Journal of Population. 2011. March. Vol. 9. № 1. P. 162–171.
Crimmins E. M., Preston S. H., Cohen B. (eds) Explaining divergent levels of
longevity in high-income countries. Washington (DC): National Academies Press (US),
2011.
Marmot M. G. Status syndrome: A challenge to medicine // JAMA. 2006. Vol. 295. №
11. P. 1304–1307.
Marmot M. The status syndrome: How social standing affects our health and
longevity. New York, NY: Henry Holt and Company, 2004.
Marmot M. G., Rose G., Shipley M., Hamilton P. J. S. Employment grade and
coronary heart disease in British civil servants // Journal of epidemiology and community
health. 1978. Vol. 32. № 4. P. 244–249.
Adler N., Ostrove J. Socioeconomic status and health: what we know and what we
don’t /Adler N., Marmot M., McEwen B., Stewart J. (eds.) Socioeconomic status and health
in industrial nations. New York, NY: New York Academy of Sciences, 1999. P. 3–15.
Mackenbach J. P., Bos V., Andersen O. et al. Widening socioeconomic inequalities in
mortality in six Western European countries // International Journal of Epidemiology. 2003.
Vol. 32. P. 830–837.
McDonough P., Duncan G. J., Williams D., House J. S. Income dynamics and adult
mortality in the United States, 1972 through 1989 // The American Journal of Public
Health. 1997. Vol. 87. № 9. P. 1476–1483.
Britton A., Shipley M., Marmot M., Hemingway H. Does access to cardiac
investigation and treatment contribute to social and ethnic differences in coronary heart
disease? Whitehall II prospective cohort study // BMJ. 2004. Vol. 329. № 7461. P. 318–323.
Closing the gap in a generation: health equity through action on the social
determinants of health. Final Report of the Commission on Social Determinants of Health.
https://t.me/medicina_free
Geneva, World Health Organization, 2008.
Franco Á., Álvarez-Dardet C., Ruiz M. T. Effect of democracy on health: ecological
study // BMJ. 2004. December 18. Vol. 329. № 7480. P. 1421–1423.
Johanson R., Newburn M., Macfarlane A. Has the medicalisation of childbirth gone
too far? // BMJ. 2002. Vol. 324. № 7342. P. 892–895.
Kaunitz A. M., Spence C., Danielson T. S., Rochat R. W., Grimes D. A. Perinatal and
maternal mortality in a religious group avoiding obstetric care // American Journal of
Obstetrics & Gynecology. 1984. December 1. Vol. 150. № 7. P. 826–831.
Stamatakis E., Weiler R., Ioannidis J. P. Undue industry influences that distort
healthcare research, strategy, expenditure and practice: a review // European journal of
clinical investigation. 2013. Vol. 43. № 5. P. 469–475.
Moynihan R., Doran E., Henry D. Disease mongering is now part of the global health
debate // PLoS Medicine. 2008. Vol. 5. № 5, e106.
Simons J. The $ 10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering
drug, has become the bestselling pharmaceutical in history. Here’s how Pfizer did it //
Fortune. 2003. January 20. Vol. 147. № 1. P. 58–62.
Лечение ОРВИ и гриппа в рутинной клинической практике // Фармацевтический
вестник. 2017. 28 июля.
Мизерницкий Ю. Л. Применение инновационного отечественного индуктора
интерферона для профилактики и лечения острых респираторных вирусных
инфекций у детей // Медицинский совет. 2016. № 1. С. 50–53.
Харламова Ф. С., Кладова О. В., Сергеева Э. М. и др. Клиническая
эффективность препарата Кагоцел® при гриппе и ОРВИ у детей с 2 до 6 лет //
Детские инфекции. 2010. № 4. С. 34–41.
Вартанян Р. В., Сергеева Э. М., Чешик С. Г. Оценка терапевтической
эффективности препарата Кагоцел® у детей младшего и дошкольного возраста с
острыми респираторными вирусными инфекциями // Детские инфекции. 2011. № 1.
С. 36–41.
Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE seeding trial:
A review of internal documents // Annals of Internal Medicine. 2008. Vol. 149. № 4. P. 251–
258.
Krimsky S., Rothenberg L. S., Stott P., Kyle G. Scientific journals and their authors’
financial interests: A pilot study // Psychotherapy and psychosomatics. 1998. July-October.
Vol. 67. № 4–5. P. 194–201.
Papanikolaou G. N., Baltogianni M. S., Contopoulos-Ioannidis D. G. et al. Reporting
of conflicts of interest in guidelines of preventive and therapeutic interventions // BMC
medical research methodology. 2001. Vol. P. 3.
Sismondo S. Ghost management: how much of the medical literature is shaped behind
the scenes by the pharmaceutical industry? // PLoS Medicine. 2007. Vol. 4. № 9, e286.
Mirowski P., Van Horn R. The contract research organization and the
commercialization of scientific research // Social studies of science. 2005. August. Vol. 35.
№ 4. P. 503–548.
Gubler A. Alternating hemiplegia, a sign of pontine lesion, and documentation of the
proof of the facial decussation / Wolf J. K. (ed.). The Classical Brainstem Syndromes.
Springfield: Charles C Thomas, 1971. P. 9–13.
https://t.me/medicina_free
Austin S. C., Stolley P. D., Lasky T. The history of malariotherapy for neurosyphilis //
JAMA. 1992. Vol. 268. № 4. P. 516–519.
Valenstein E. S. Great and desparate cures: The rise and decline of psychosurgery and
other radical treatments for mental illness. New York: Basic Books, 1986.
EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to
reduce the risk of ischemic stroke. Results of an international randomized trial // The New
England journal of medicine. 1985. November 7. Vol. 313. № 19. P. 1191–1200.
Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients
receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The
New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.
Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in
america’s worst drug disaster. New York: Simon and Schuster, 1995.
Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy
in acute myocardial infarction. An overview of results from randomized trials // JAMA.
1993. October 6. Vol. 270. № 13. P. 1589–1595.
Eclampsia Trial Collaborative Group. Which anticonvulsant for women with
eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.
Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al.
Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1,
h4534.
Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of
Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.
Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4.
P. I26–13I.
Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’
in developed countries // Journal of epidemiology and community health. 1978. September.
Vol. 32. № 3. P. 200–205.
Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and
variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.
Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors
strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.
Global, regional, and national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease
Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.
Global, regional, and national incidence, prevalence, and years lived with disability
for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic
analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386.
№ 9995. P. 743–800.
Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? //
Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.
Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in
hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol.
279. № 15. P. 1200–1205.
Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol.
284. № 4. P. 483–485.
https://t.me/medicina_free
Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths
between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.
Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating
healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health
Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.
Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-
illness model // Journal of the American Pharmaceutical Association. 2001. March/April.
Vol. 41. № 2. P. 192–199.
Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness
model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–
47.
Sturkenboom M. C., Romano F., Simon G., Correa-Leite M. L., Villa M. et al. The
iatrogenic costs of NSAID therapy: a population study // Arthritis and rheumatism. 2002
April 15. Vol. 47. № 2. P. 132–140.
Weingart S. N., Wilson R. McL., Gibberd R. W., Harrison B. Epidemiology of medical
error // BMJ. 2000. March 18. Vol. 320. № 7237. P. 774–777.
Hayward R. A., Hofer T. P. Estimating hospital deaths due to medical errors:
preventability is in the eye of the reviewer // JAMA. 2001. Vol. 286. № 4. P. 415–420.
Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B.
Impotence and its medical and psychosocial correlates: results of the Massachusetts Male
Aging Study // The Journal of urology. 1994. January. Vol. 151. № 1. P. 54–61.
Araujo A. B., Johannes C. B., Feldman H. A., Derby C. A., McKinlay J. B. Relation
between psychosocial risk factors and incident erectile dysfunction: prospective results
from the Massachusetts male aging study // American Journal of Epidemiology. 2000.
September 15. Vol. 152. № 6. P. 533–541.
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction // PLoS
Medicine. 2006. Vol. 3. № 4, e132.
Sample I. Viagra: The profitable pill // The Guardian. 2009. November 16.
Moynihan R. The making of a disease: female sexual dysfunction // BMJ. 2003.
January 4. Vol. 326. № 7379. P. 45–47.
Critser G. Generation Rx: How prescription drugs are altering American lives, minds,
and bodies. Boston: Houghton-Mifflin, 2005.
Laumann E. O., Paik A., Rosen R. C. Sexual dysfunction in the United States:
prevalence and predictors // JAMA. 1999. Vol. 281. № 6. P. 537–544.
Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and
disease mongering // BMJ. 2002. April 13. Vol. 324. № 7342. P. 886–891.
Clark D. Between hope and acceptance: the medicalisation of dying // BMJ. 2002.
April 13. Vol. 324. № 7342. P. 905–907.
Gilbert D., Walley T., New B. Lifestyle medicines // BMJ. 2000. November 25. Vol.
321. № 7272. P. 1341–1344.
Maggini M., Vanacore N., Raschetti R. Cholinesterase inhibitors: drugs looking for a
disease? // PLoS Medicine. 2006. Vol. 3. № 4, e140.
Phillips C. B. Medicine goes to school: Teachers as sickness brokers for ADHD //
PLoS Medicine. 2006. Vol. 3. № 4, e182.
https://t.me/medicina_free
Healy D. The latest mania: Selling bipolar disorder // PLoS Medicine. 2006. Vol. 3. №
5, e236.
Scott S. The medicalisation of shyness: from social misfits to social fitness // Sociology
of Health & Illness. 2006. Vol. 28. № 2. P. 133–153.
Wolinsky H. Disease mongering and drug marketing // EMBO reports 2005. Vol. 6. №
7. P. 612–614.
Woloshin S., Schwartz L. M. Giving legs to restless legs: A case study of How the
media helps make people sick // PLoS Medicine. 2006. Vol. 3. № 4, e170.
Gagnon M.-A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical
promotion expenditures in the United States // PLoS Medicine. 2008. Vol. 5. № 1, e1.
Branding the cure: a consumer perspective on corporate social responsibility, drug
promotion and the pharmaceutical industry in Europe. London: Consumers International,
2006.
Matheson A. The disposable author: how pharmaceutical marketing is embraced
within medicine’s scholarly literature // Hastings Center Report. 2016. July/August. Vol. 46.
№ 4. P. 31–37.
Giannakakis I. A., Ioannidis J. P. A. Arabian nights – 1001 tales of how
pharmaceutical companies cater to the material needs of doctors: case report // BMJ. 2000.
December 23. Vol. 321. № 7276. P. 1563–1564.
Donohue J. M., Cevasco M., Rosenthal M. B. A decade of direct-to-consumer
advertising of prescription drugs // The New England journal of medicine. 2007. Vol. 357.
№ 7. P. 673–681.
Applbaum K. Is marketing the enemy of pharmaceutical innovation? // Hastings
Center Report. 2009. July-August. Vol. 39. № 4. P. 13–17.
Ioannidis J. P. A. Mega-trials for blockbusters // JAMA. 2013. January 16. Vol. 309.
№ 3. P. 239–240.
Moffatt B., Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten
journal articles // Perspectives in Biology and Medicine. 2007.·February. Vol. 50. № 1. P.
18–31.
Goldbloom D. S. Physicians and the pharmaceutical industry // CPA Bulletin de
l’APC. 2003. October. P. 3–4.
Goldbloom D. S. Les médecins et l’industrie pharmaceutique // CPA Bulletin de
l’APC. 2003. October. P. 4–5.
Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? //
JAMA. 2000. Vol. 283. № 3. P. 373–380.
Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician
prescribing patterns. There’s no such thing as a free lunch // Chest. 1992. Vol. 102. № 270–
273.
Grande D., Frosch D. L., Perkins A. W., Kahn B. E. Effect of exposure to small
pharmaceutical promotional items on treatment preferences // Archives of Internal
Medicine. 2009. Vol. 169. № 9. P. 887–893.
Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a
systematic review // BMJ Quality & Safety. 2005. Vol. 14. P. 246–250.
Frosch D. L., Krueger P. M., Hornik R. C., Cronholm P. F., Barg F. K. Creating
demand for prescription drugs: a content analysis of television direct-to-consumer
https://t.me/medicina_free
advertising // Annals of family medicine. 2007. January-February. Vol. 5. № 1. P. 6–13.
Ventola C. L. Direct-to-consumer pharmaceutical advertising. Therapeutic or Toxic? //
P & T: a peer-reviewed journal for formulary management. 2011. October. Vol. 36. № 10. P.
669–684.
Frosch D. L., Grande D., Tarn D. M., Kravitz R. L. A decade of controversy:
balancing policy with evidence in the regulation of prescription drug advertising //
American journal of public health. 2010. January. Vol. 100. № 1. P. 24–32.
Experimental evaluation of the impact of distraction on consumer understanding of
risk and benefit information in direct-to-consumer prescription drug television
advertisements. 2011. June.
Grimes T. Mild auditory-visual dissonance in television news may exceed viewer
attentional capacity // Human Communication Research. 1991. December 1. Vol. 18. № 2.
P. 268–298.
Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R. et al. Influence of
patients’ requests for direct-to-consumer advertised antidepressants: a randomized
controlled trial // JAMA. 2005. April 27. Vol. 293. № 16. P. 1995–2002.
Mintzes B., Barer M. L., Kravitz R. L., Kazanjian A., Bassett K., Lexchin J. et al.
Influence of direct to consumer pharmaceutical advertising and patients’ requests on
prescribing decisions: two site cross sectional survey // British Medical Journal. 2002. Vol.
324. № 7332. P. 278–279.
Hochhauser M. Is this a seeding trial? // Journal of Clinical Research Best Practices.
2009. June. Vol. 5. № 6.
Vedula S. S., Bero L., Scherer R. W., Dickersin K. Outcome reporting in industry-
sponsored trials of gabapentin for off-label use // The New England Journal of Medicine.
2009. № 20. Vol. 361. P. 1963–1971.
Sox H. C., Rennie D. Seeding trials: just say “No” // Annals of Internal Medicine
(Editorial). 2008. August 19. Vol. 149. № 4. P. 279–280.
Kuriya B., Schneid E. C., Bell C. M. Quality of pharmaceutical industry press releases
based on original research // PLoS ONE. 2008. Vol. 3. № 7, e2828.
Woloshin S., Schwartz L. M. Press releases: translating research into news // JAMA.
2002. Vol. 287. № 21. P. 2856–2858.
Yavchitz A., Boutron I., Bafeta A., Marroun I., Charles P., Mantz J. et al.
Misrepresentation of randomized controlled trials in press releases and news coverage: a
cohort study // PLoS Med. 2012. Vol. 9. № 9, e1001308.
Welch H. G., Black W. C. Overdiagnosis in Cancer // Journal of the National Cancer
Institute. 2010. May 5. Vol. 102. № 9. P. 605–613.
Барчук А., Талантов П. Война на опережение. Скрининг не станет очередной
панацеей от рака, нужно менять привычки людей // Новая газета. 2018. 17 сентября.
№ 102.
Marmot M. G., Altman D. G., Cameron D. A., Dewar J. A., Thompson S. G., Wilcox
M. The benefits and harms of breast cancer screening: an independent review // British
Journal of Cancer. 2013. June 11. Vol. 108. № 11. P. 2205–2240.
Gøtzsche P. C., Nielsen M. Screening for breast cancer with mammography (Review).
Cochrane Database of Systematic Reviews. 2011. № 4.
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана